Business
NikeSKIMS
(Nike & Skims)

Nike, trying to break out of its funk, launches its high-stakes collab with Kim Kardashian’s Skims

The partnership champions women athletes and tests how far Kim K’s star power can stretch in the women’s activewear arena.

Two juggernauts, one stretchy debut.

After months of hype, Nike and Kim Kardashian’s Skims are dropping their first-ever collection Friday, merging a global sportswear giant with one of fashion’s fastest-growing brands.

Wall Street seems optimistic: Jefferies analysts called the collab a “new bar” for Nike in a note on Monday, reiterating their “buy” rating on the stock and $115 price target, or about 65% above current levels. Nikes investors were already on the hype train about the partnership, bidding shares up 6.2% on the day it was announced in February.

Nike could use some optimism. The company has been working through a turnaround after sales pressure in its key US and China markets, including swapping its CEO about a year ago. Its stock has been pummeled: down 21% over the past year and 44% over the past five. This launch offers a chance to win back female shoppers and draw fresh attention as the brand looks to regain its footing.

The new NikeSKIMS line, marketed as “designed to sculpt and engineered to perform,” includes seven collections and 58 silhouettes with more than 10,000 possible combinations. It’s available on both the Skims and Nike websites, as well as at select retail locations.

The Nike Skims collection was originally slated for spring 2025 but was delayed due to production issues.

On Thursday, the brands premiered Bodies at Work, a marketing film featuring more than 50 athletes from Nike’s roster, including Serena Williams, Sha’Carri Richardson, and collegiate stars from USC and UCLA.

Since launching Skims in 2019 with entrepreneur Jens Grede, Kardashian has built the brand into a cultural force by filling gaps in the athleisure market with broader sizing, diverse shade ranges, and more versatile styles than rivals like Lululemon and Alo, while driving buzz through high-profile collaborations. 

Last December, the Skims x North Face ski collection sold out in hours. In June, a swimwear collaboration with Roberto Cavalli sold out almost immediately, with some pieces later fetching higher resale prices on StockX.

Skims’ hype has translated into hard numbers: Skims was valued at $4 billion in 2023 after raising $270 million and reportedly pulled in about $900 million in revenue that year. It opened its first flagship store on New York’s Fifth Avenue last year and continues to expand its retail footprint. In August, the brand hired a former Michael Kors executive to lead expansion across Europe, the Middle East, and Africa, with Dubai and London flagship locations already in the works.

For Skims and Kardashian, a successful rollout could further cement her brand as a lucrative partner for both sales and social clout.

Nike is set to report earnings next Tuesday.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.